SJP-1801

SJP-1801 is a sponsor code for an experimental drug candidate from Samjin Pharmaceuticals that has been publicly associated with development for neurodegenerative disorders including Alzheimer's disease and Parkinson's disease. Publicly accessible sources confirm the existence of the program name and link it to Samjin's pipeline, but they do not provide sufficient detail on the molecular identity, modality, mechanism of action, target biology, formulation, route of administration, or clinical stage specifics. Secondary pipeline aggregators also indicate that the program was later discontinued, but because the available public evidence is sparse and largely non-primary, SJP-1801 should currently be treated as a minimally characterized Samjin pipeline asset rather than a well-described clinical candidate.